RILPIVIRINE Pharmacologic Class Indexing
- Class set ID
- 52dc82a8-32f5-4e15-8deb-531bde39f03c
- Version
- 3
- Effective date
- 20181113
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EMTRICITABINE, RILPIVIRINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2011 | Laurus Labs Limited | Laurus Labs Limited (VSP2) | 20260305 | 1 |
| These highlights do not include all the information needed to use RILPIVIRINE TABLETS safely and effectively. See full prescribing information for RILPIVIRINE TABLETS RILPIVIRINE tablets, for oral use Initial U.S. Approval:2011 | Somerset Therapeutics, LLC | Piramal Pharma Limited | 20260205 | 1 |
| These highlights do not include all the information needed to use ODEFSEY safely and effectively. See full prescribing information for ODEFSEY. ODEFSEY ® (emtricitabine, rilpivirine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2016 | Gilead Sciences, Inc. | 20251202 | 13 |
| These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021 | ViiV Healthcare Company | Glaxo Wellcome Manufacturing Pte. Ltd | Janssen Pharmaceutica NV | 20251126 | 16 |
| These highlights do not include all the information needed to use JULUCA safely and effectively. See full prescribing information for JULUCA. JULUCA (dolutegravir and rilpivirine tablets), for oral use Initial U.S. Approval: 2017 | ViiV Healthcare Company | 20251029 | 15 |
| These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. EDURANT ® (rilpivirine) tablets, for oral use EDURANT ® PED (rilpivirine) tablets, for oral suspension Initial U.S. Approval: 2011 | Janssen Products, LP | AndersonBrecon Inc | Janssen Pharmaceutica NV | Janssen-Cilag SpA | Johnson & Johnson Private Limited | Janssen Pharmaceutical Sciences Unlimited Company | 20250828 | 28 |
| These highlights do not include all the information needed to use COMPLERA safely and effectively. See full prescribing information for COMPLERA. COMPLERA ® (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2011 | Gilead Sciences, Inc. | 20250716 | 21 |
| These highlights do not include all the information needed to use COMPLERA safely and effectively. See full prescribing information for COMPLERA. COMPLERA™ (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets, for oral use GILEAD ACCESS PROGRAM Initial U.S. Approval: 2011 | Gilead Sciences, Inc. | 20250716 | 10 |
| These highlights do not include all the information needed to use EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EMTRICITABINE, RILPIVIRINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2011 | Mylan Pharmaceuticals Inc. | 20241214 | 1 |
| These highlights do not include all the information needed to use ODEFSEY safely and effectively. See full prescribing information for ODEFSEY. ODEFSEY ® (emtricitabine, rilpivirine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2016 | A-S Medication Solutions | 20180110 | 4 |
| These highlights do not include all the information needed to use COMPLERA safely and effectively. See full prescribing information for COMPLERA. COMPLERA ® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2011 | Physicians Total Care, Inc. | 20130315 | 1 |